28 Thymic Tumor Clinical Trials Recruiting Now (May 2026): Thymoma, Thymic Carcinoma, IO + Chemo, Proton + Carbon Ion, FUSCC-Thymic 3
Last updated: May 29, 2026
Current Clinical Trial Landscape
Thymic epithelial tumors include:
- Thymoma — slower growing, often associated with myasthenia gravis
- Thymic carcinoma — more aggressive, higher recurrence risk
Active research areas in 2026:
- Advanced radiotherapy: proton and carbon ion — multiple Phase 3 trials for postoperative residual disease
- Checkpoint inhibitor + multikinase combinations (pembrolizumab + lenvatinib, tislelizumab + anlotinib)
- Neoadjuvant chemoradiation + immunotherapy for locally advanced unresectable disease
- Adjuvant strategy refinement (post-operative chemo + RT optimization, conformal RT)
- Novel single agents (PT-112) in pretreated thymoma + thymic carcinoma
Standard of care: Surgery for resectable disease. Unresectable: platinum-based chemotherapy (cisplatin + doxorubicin + cyclophosphamide or carboplatin + paclitaxel).
Recruiting Trials by Treatment Setting
First-Line / Newly Diagnosed
For previously untreated advanced or unresectable thymic tumors:
- NCT05832827 - Carboplatin/Paclitaxel + Lenvatinib + Pembrolizumab (first-line)
- NCT06730308 - Glucocorticoids + concurrent chemoradiotherapy for unresectable thymoma
Second-Line / Refractory
After progression on first-line therapy:
Adjuvant / Post-Surgery
After surgical resection to reduce recurrence:
- NCT02633553 - Adjuvant radiotherapy for stage II/III thymoma after complete resection
- NCT06311955 - Postoperative carbon ion radiotherapy for residual disease
- NCT06311968 - Postoperative proton radiotherapy
- NCT06402708 - Postoperative adjuvant chemotherapy for thymic cancer (FUSCC-Thymic 3, Phase 3)
- NCT04731610 - Conformal post-operative radiotherapy in resected thymic tumors (Phase 3)
Neoadjuvant / Pre-Surgery
- NCT06924619 - Neoadjuvant radiotherapy for locally advanced unresectable thymoma
- NCT06019468 - Neoadjuvant treatment for locally advanced thymic cancer (Phase 2)
Trials by Treatment Approach
Radiotherapy (14 trials)
Proton therapy and carbon ion radiotherapy offer precise tumor targeting with less damage to surrounding tissue. View all →
Chemotherapy (8 trials)
Platinum-based combinations remain a backbone of treatment for advanced disease. View all →
Checkpoint Inhibitors (4 trials)
PD-1 inhibitors show activity but require careful monitoring due to autoimmune risks (myasthenia gravis). View all →
Frequently Asked Questions
How do I find thymic tumor clinical trials?
Paste your medical summary into ClinTrialFinder to get AI-matched thymic tumor trials in minutes. The tool considers your WHO classification, disease stage, and prior treatments for both thymoma and thymic carcinoma.
What thymic tumor trials are currently recruiting?
There are 28 recruiting interventional trials for thymic tumors including pembrolizumab + lenvatinib + carboplatin/paclitaxel first-line, tislelizumab + anlotinib second-line, novel single agents like PT-112, neoadjuvant chemoradiation, postoperative carbon ion + proton + conformal radiotherapy trials, and FUSCC-Thymic 3 (NCT06402708) adjuvant chemotherapy Phase 3 for both thymoma and thymic carcinoma.
Find Thymic Tumor Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.
Find Matching Trials
